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Peripheral blood natural killer (NK) cells from patients with transporter associated with antigen processing (TAP) deficiency are
hyporesponsive. The mechanism of this defect is unknown, but the phenotype of TAP-deficient NK cells is almost normal.
However, we noticed a high percentage of CD56
bright cells among total NK cells from two patients. We further investigated
TAP-deficient NK cells in these patients and compared them to NK cells from two other TAP-deficient patients with no clinical
symptoms and to individuals with chronic inflammatory diseases other than TAP deficiency (chronic lung diseases or
vasculitis). Peripheral blood mononuclear cells isolated from venous blood were stained with fluorochrome-conjugated
antibodies and the phenotype of NK cells was analyzed by flow cytometry. In addition,
51Chromium release assays were
performed to assess the cytotoxic activity of NK cells. In the symptomatic patients, CD56
bright NK cells represented 28% and
45%, respectively, of all NK cells (higher than in healthy donors). The patients also displayed a higher percentage of
CD56
dimCD16
2 NK cells than controls. Interestingly, this unusual NK cell subtype distribution was not found in the two
asymptomatic TAP-deficient cases, but was instead present in several of the other patients. Over-expression of the inhibitory
receptor CD94/NKG2A by TAP-deficient NK cells was confirmed and extended to the inhibitory receptor ILT2 (CD85j). These
inhibitory receptors were not involved in regulating the cytotoxicity of TAP-deficient NK cells. We conclude that expansion of
the CD56
bright NK cell subtype in peripheral blood is not a hallmark of TAP deficiency, but can be found in other diseases as
well. This might reflect a reaction of the immune system to pathologic conditions. It could be interesting to investigate the
relative distribution of NK cell subsets in various respiratory and autoimmune diseases.
Citation: Zimmer J, Bausinger H, Andre `s E, Donato L, Hanau D, et al (2007) Phenotypic Studies of Natural Killer Cell Subsets in Human Transporter
Associated with Antigen Processing Deficiency. PLoS ONE 2(10): e1033. doi:10.1371/journal.pone.0001033
INTRODUCTION
Human natural killer (NK) cells are phenotypically defined as
CD3
2CD56
+ lymphocytes. They constitute a heterogeneous
blood cell population and subsets can be defined depending on
their level of expression of CD16 and CD56. In healthy
individuals, CD56
dimCD16
bright cells represent at least 90% of
all NK cells [1]. Most of the other NK cells belong to the
CD56
bright subset that can be further subdivided in a CD16
2 (30–
50% of CD56
bright) and a CD16
dim (50–70% of CD56
bright)
fraction [1]. Finally, minor subpopulations with a CD56
dimCD16
2
and conversely CD56
2CD16
+ phenotype have been described [2].
The major functional properties of NK cells are cytotoxicity and
cytokine production, which are governed by a balance between
activating messages transmitted by activating receptors (AR) and
inhibitory signals transmitted by inhibitory receptors (IR), re-
spectively [3–5]. Activating receptors recognize ligands expressed
by tumor cells or stressed cells or, in the case of CD16, antibodies
(Ab) of the IgG class bound to target cells. Among the IR, those
specific for human leukocyte antigen (HLA) class I molecules
recognize either (i) restricted numbers of classical HLA class I
alleles in the case of killer immunoglobulin receptors (KIR), (ii)
a broad panel of classical HLA class I molecules as well as HLA-G
in the case of immunoglobulin-like transcript 2 (ILT2 or CD85j)
and (iii) the non classical major histocompatibility complex (MHC)
class I molecule HLA-E presenting peptides derived from the
signal sequence of classical HLA class I molecules in the case of
CD94/NKG2A [4,5]. In addition, NK cells express also several
IR with ligands different from HLA class I molecules [6].
HLA class I molecules present endogenous peptides to cytotoxic
CD8
+ T cells. Newly synthesized HLA class I molecules acquire
their peptidic ligands in the endoplasmic reticulum (ER) [7–9].
Most of these peptides that result from the degradation of
endogenous proteins by the proteasome are translocated into the
lumen of the ER by the transporter associated with antigen
processing (TAP). TAP is expressed as a heterodimer of two
subunits, TAP1 and TAP2, and is inserted in the membrane of the
ER. In the absence of a functional TAP, only a very limited
amount of peptides can reach the lumen of the ER and associate
Academic Editor: Nina Papavasiliou, The Rockefeller University, United States of
America
Received May 24, 2007; Accepted September 25, 2007; Published October 17,
2007
Copyright:  2007 Zimmer et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: The ‘‘Laboratoire d’Immunoge ´ne ´tique-Allergologie’’ is supported by an
institutional grant from the ‘‘CRP-Sante ´’’, Luxembourg. The work of Jacques
Zimmer was partially financed by a grant (BFR 96/003) from the ‘‘Ministe `re de la
Culture, de l’Enseignement Supe ´rieur et de la Recherche’’ (Ministry of Culture,
Higher Education and Research) of Luxembourg.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: jacques.zimmer@crp-
sante.lu
PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1033with HLA class I molecules. Consequently, most of these
molecules remain unstable and never reach the cell surface [7–9].
Nineteen human cases of TAP deficiency have to date been
described [10–23]. Clinically, this recessive autosomal disease is
very heterogeneous, the spectrum of possible manifestations
extending from the complete absence of symptoms [11,21] to
life-threatening conditions [11,18]. Most frequently, the patients
suffer from chronic bacterial infections of the upper and lower
airways, evolving to bronchiectasis, and in approximately half of
the cases also from skin ulcers with features of a chronic
granulomatous inflammation [10,11]. Recent observations also
describe the occurrence of ocular and pulmonary toxoplasmosis
[22,23]. Surprisingly however, severe viral infections have never
been reported in these patients, despite the defect in HLA class
I-mediated presentation of viral antigens to cytotoxic T cells. It is
assumed that other antiviral defense mechanisms like antibodies,
non HLA class I-restricted cytotoxic effector cells (cd T
lymphocytes, NK cells) and CD8
+ T cell responses to TAP-
independent antigens are sufficiently efficient [10,11].
The symptomatic patients have a very large (30- to 100-fold)
reduction in the cell surface expression levels of HLA class I
molecules, as compared to healthy individuals [10,11]. As NK cells
preferentially kill target cells with low or absent HLA class I
molecules on the surface [4], we previously investigated suscep-
tibility of autologous cells to NK cell-mediated lysis in two TAP-
deficient patients. TAP-deficient cells are killed by TAP
+ normal
NK cells but not by autologous resting NK cells. Nevertheless,
resting TAP
2 NK cells are able to perform antibody-dependent
cellular cytotoxicity (ADCC) to some extent, and after stimulation
with interleukin (IL) 2, they become cytotoxic not only towards
tumor cell lines, but also to two types of autologous cells, namely
Epstein-Barr virus (EBV)-transformed B lymphoblasts [24] and
skin fibroblasts [25]. Their repertoire of AR and IR is almost
normal, although CD94/NKG2A is expressed at much higher
levels than by normal NK cells [24]. Not only AR, but also IR are
functional [24,26], as assessed using activated TAP
2 NK cells in
cytotoxicity tests against allogeneic normal cells. Thus, the
mechanism responsible for the hyporesponsiveness of resting
TAP-deficient NK cells is still unknown.
Previous investigations also revealed a higher than normal
percentage of CD56
bright cells among the patients’ NK cells [26].
Theobjectiveofourstudywas to investigateifthe highpercentageof
CD56
bright NK cells and the over-expression of NKG2A were
constant findings in TAP deficiency, and if these features could also
be observed in diseases of other origins. Therefore, we compared by
flow cytometry peripheral blood NK cells from the symptomatic
TAP-deficient patientsto thosefrom two asymptomatic patients [21]
as well as to a small panel of individuals with respiratory diseases of
etiologies different from TAP deficiency and of vasculitis patients. A
group of normal control donors was also included.
METHODS
Participants
Blood samples were obtained from volunteers or patients attending
the clinics of Strasbourg University Hospitals and were collected
during routine clinical (diagnostic/prognostic/therapeutic) proce-
dures prescribed by two co-authors, Pr. E. Andre `s and Dr. L.
Donato. Before blood samples were collected for the study, all
healthy donors, all patients and, for those patients who were minor
at the time of blood sampling, their parents, gave written informed
consent in agreement with the Helsinki Declaration and French
legislation, under which no approval by an Ethics Committee was
required in this case.
We included four patients with a known TAP deficiency
[12,21], two patients with a known cystic fibrosis, five patients with
chronic respiratory diseases complicated by acute infections, five
patients with chronic respiratory diseases but no acute infection,
and five vasculitis patients. The inclusion in one or another group
was decided on the basis of clinical and biological parameters by
the above mentioned physicians. As our study was intended as
preliminary and as potential indicator for the interest of future
large scale investigations, we deliberately limited the size of the
different groups, and no sample size calculations were performed.
In addition, we included seventeen volunteer donors (the same
number as patients with no TAP deficiency) with no apparent
signs of disease.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from
citrated venous blood by Ficoll-Hypaque density gradient
centrifugation and either used directly for flow cytometry or
frozen in RPMI 1640 culture medium with 20% fetal calf serum
(FCS) and 10% dimethylsulfoxyde (DMSO).
For flow cytometry stainings, PBMC were washed at 4uC, once
in RPMI 1640/10% FCS and once in phosphate buffered saline
(PBS) with 3% FCS (staining buffer). Cells were then resuspended
in ice-cold staining buffer at 5610
6 cells/ml and stained in aliquots
of 100 ml with various purified or fluorochrome-conjugated Ab at
optimal concentrations previously determined by titration. The Ab
and fluorochromes used are listed in table 1. They were purchased
from Beckman Coulter (Margency, France), with the exception of
HP-F1 (anti-ILT2), generously provided by Pr. Miguel Lo ´pez-
Botet, University Pompeu Fabra, Barcelona, Spain, and Z199
(anti-NKG2A), produced in one of our labs and previously
described [27]. After incubation in the dark, at 4uC, for
30 minutes, cells were washed twice in ice-cold staining buffer
and fixed in Cytofix solution (BD Biosciences, Erembodegem,
Belgium). In the case of cells first stained with purified Ab, they
were washed, incubated with a secondary PE-conjugated goat
anti-mouse Ab (Dako, Glostrup, Denmark), washed again,
incubated in mouse serum for 20 minutes, washed once more,
and finally stained with fluorochrome-conjugated Ab as described
above. Stained cells were kept in the dark at 4uC until flow
cytometry, that was performed on a FACSCalibur
TM flow
cytometer (BD Biosciences). Results were analyzed with Cell-
quest
TM software (BD Biosciences). The region of living lympho-
cytes was gated based on forward and side scatter characteristics,
and at least 2500 NK cells per sample were acquired.
Table 1. Antibodies used for flow cytometry
......................................................................
antibody (clone
name) fluorochrome antigen supplier
T11 FITC CD2 Beckman Coulter
UCHT1 FITC or PC5 CD3 Beckman Coulter
3G8 FITC CD16 Beckman Coulter
J4.119 FITC or PC5 CD19 Beckman Coulter
N901 (NKH-1) PE or PC5 CD56 Beckman Coulter
HP-F1 PE* CD85j (ILT2) Pr. M. Lo ´pez-Botet
Z199 PE* CD159 (NKG2A) Pr. A. Moretta [27]
FITC : fluorescein isothiocyanate ; PE : phycoerythrin ; PC5 : phycoerythrin-
cyanin 5. *: indirect staining; cells were first stained with the indicated purified
Ab, washed, and then stained with a secondary goat anti-mouse Ab conjugated
to PE. All other Ab were used in directly fluorochrome-conjugated forms.
doi:10.1371/journal.pone.0001033.t001
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NK Cells in TAP Deficiency
PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e1033Cytotoxicity Assays
Activated NK cells and phytohemagglutinin (PHA)-induced T cell
blasts were obtained in culture as previously described [26]. For
the assessment of NK cell cytotoxicity, standard four hour
51Chromium release assays were performed as previously de-
scribed [24,26] in the absence or presence of masking Ab used at
a concentration of 10 mg/ml.
RESULTS
High percentage of CD56
bright NK cells in some
patients with TAP deficiency but also chronic
diseases of other origins
To confirm and extend our previous findings about the high
percentage of CD56
bright NK cells in two TAP-deficient patients
[26], we stained PBMC from these individuals and from seven
healthy donors with anti-CD3, -CD19, -CD16 and -CD56 Ab.
Within the gate of CD3
2CD19
2 lymphocytes corresponding to
NK cells, we analyzed CD16 versus CD56 expression. As shown in
figure 1 and in table 2, it appeared indeed that the two patients
had a very high percentage of CD56
bright NK cells compared to
normal donors. CD56
bright NK cells were distributed quite equally
between the CD16
2 and CD16
dim subsets in patient EMO,
whereas the CD16
dim population was predominant in patient
EFA. In addition, both patients also had a higher percentage of
CD56
dimCD16
2 NK cells (table 2).
Table 2. NK cell subsets in TAP-deficient patients and healthy
control donors
......................................................................
CD56
bright
CD16
2
CD56
bright
CD16
dim
Total
CD56
bright
CD56
dim
CD16
bright
CD56
dim
CD16
2
HD 1 3.51 1.66 5.17 91.38 3.45
HD 2 2.12 0.34 2.46 96.27 1.27
HD 3 1.35 0.75 2.10 97.20 0.70
HD 4 1.35 0.75 2.10 94.70 3.20
HD 5 4.18 4.29 8.47 91.36 0.17
HD 6 4.57 3.24 7.81 92.14 0.05
EHA (HD 7) 3.55 2.98 6.53 92.05 1.42
EFA 8.56 19.46 28.02 52.82 19.16
EMO 21.93 23.82 45.75 42.11 12.14
SFH 5.16 3.19 8.35 86.37 5.28
DFH 2.65 2.08 4.73 92.04 3.23
Values correspond to the cells in the different subsets expressed as percentages
of total peripheral blood NK cells. HD: healthy donor; EHA: father of patients
EFA and EMO; EFA, EMO: symptomatic TAP2-deficient patients (siblings); SFH,
DFH: asymptomatic TAP2-deficient patients (siblings).
doi:10.1371/journal.pone.0001033.t002
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Figure 1. High percentages of CD56
bright NK cells in two symptomatic TAP-deficient patients. PBMC from four normal donors and the patients
were stained with fluorochrome-conjugated antibodies and analyzed by flow cytometry. Expression of CD16 and CD56 is shown on gated
CD3
2CD19
2 lymphocytes (one representative experiment). Percentages of CD56
bright NK cells among total NK cells are indicated for each donor.
doi:10.1371/journal.pone.0001033.g001
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1033As CD56
bright NK cells are less cytotoxic than CD56
dim NK cells
[1,28], their high percentage in TAP-deficient patients might reflect
an adaptation to the low HLA class I expression in order to avoid
cytotoxicity toward autologous targets. In that case, a similar
distribution of NK cell subsets should be observed in other TAP-
deficient individuals. Therefore, we looked at PBMC from two
additional patients, SFH and DFH [21], and found that their
CD56
bright NK cells represented 8% and 4% of all peripheral blood
NK cells, respectively (table 2). They were thus within the normal
range (,10% of NK cells), as were the CD56
dimCD16
2 cells.
In the absence of a systematic expansion of the CD56
bright NK
cell fraction in TAP-deficient patients, an alternative explanation
for the values observed in patients EFA and EMO could be that
CD56
bright NK cells become more abundant as a reaction to an
acute infection or to the chronic inflammatory state present in
these patients (whereas patients SFH and DFH were asymptom-
atic). Should this be true, higher than normal percentages of
CD56
bright NK cells might also be found in patients with no TAP
deficiency but with acute or chronic infections and/or inflamma-
tory diseases of other origins.
We thus repeated the stainings described above in a small series
of patients mentioned in the Methods section. Details about these
patients are listed in table 3. HLA class I deficiency was ruled out
in all of them by flow cytometry staining of PBMC with the pan
anti-HLA class I Ab W6/32 (data not shown). We also included
a panel of healthy donors. The results summarized in table 4
revealed, in accordance with our hypothesis, a percentage of the
CD56
bright population clearly above 10% of all peripheral blood
NK cells in five of the seventeen patients (29.41%) and even in
three of the ten healthy donors (30%). Regarding the
CD56
dimCD16
2 NK cell subtype, it was higher than 10% in four
patients (23.53%), of whom only one also displayed a high
percentage of CD56
bright NK cells in parallel (table 4).
Over-expression of NKG2A on both CD56
bright
and CD56
dim NK cells from two TAP-deficient
patients
The previously reported over-expression of the IR CD94/
NKG2A by NK cells from patients EFA and EMO [24] could
likewise be interpreted as an adaptation of NK cells to the low
levels of HLA class I molecules in these patients, because it might
allow to avoid autoreactivity, at least to some extent. However, as
it is known that mean fluorescence intensities (MFI) of NKG2A
are much higher on CD56
bright than on CD56
dim NK cells [1,28],
the observed over-expression of NKG2A in EFA and EMO might
simply be a consequence of the high percentage of CD56
bright NK
cells and would not necessarily reflect a regulatory mechanism. To
address this point, we stained PBMC from EFA and EMO, SFH,
DFH, the seventeen healthy donors and the seventeen patients
with diseases other than TAP deficiency with anti-CD3, -CD19,
-CD56 and -NKG2A Ab and analyzed NKG2A expression in
terms of percentages of positive cells and MFI on gated
CD3
2CD19
2CD56
+ NK cells. Among CD56
bright NK cells,
more than 90% expressed NKG2A in the vast majority of healthy
donors as well as patients (mean: 90.75%, range: 56–100%). Much
Table 3. Characteristics of patients with diseases other than
TAP deficiency
......................................................................
patient
number gender age* diagnosis
1 F 5 cystic fibrosis
2 F 14 cystic fibrosis
3 M 71 chronic respiratory insufficiency, acute infection
4 M 72 COPD, acute infection
5 M 43 bronchiectasis, acute infection
6 M 59 chronic respiratory insufficiency, acute infection
7 F 88 chronic respiratory insufficiency, acute infection
8 M 86 COPD, no acute infection
9 M 74 COPD, no acute infection
10 F 81 chronic respiratory insufficiency,
pneumoconiosis
11 F 72 chronic respiratory insufficiency
12 M 71 chronic respiratory insufficiency
13 F 92 cryoglobulinemia, leucocytoclastic vasculitis
14 F 27 vasculitis
15 F 88 suspected vasculitis
16 F 43 vasculitis
17 F 76 vasculitis
age*: age at the time of blood sampling; F: female; M: male; COPD: chronic
obstructive pulmonary disease.
doi:10.1371/journal.pone.0001033.t003
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 4. NK cell subsets in additional healthy donors and
patients with diseases other than TAP deficiency
......................................................................
CD56
bright
CD16
2
CD56
bright
CD16
dim
Total
CD56
bright
CD56
dim
CD16
bright
CD56
dim
CD16
2
HD 8 3.63 3.09 6.72 88.94 4.34
HD 9 4.56 3.42 7.98 89.52 2.50
HD 10 5.78 3.30 9.08 88.79 2.13
HD 11 11.43 5.54 16.97 80.00 3.03
HD 12 11.93 3.03 14.96 79.41 5.63
HD 13 8.56 4.60 13.16 82.38 4.46
HD 14 3.60 3.24 6.84 91.04 2.12
HD 15 2.66 3.75 6.41 92.24 1.25
HD 16 3.20 1.71 4.91 85.34 9.75
HD17 3.08 0.39 3.47 95.76 0.77
1 7.45 5.54 12.99 85.25 1.76
2 3.91 0.00 3.91 83.59 12.50
3 2.97 1.16 4.07 91.75 4.18
4 1.76 1.23 2.99 94.25 2.76
5 8.30 4.30 12.60 81.88 5.52
6 6.74 18.19 24.95 68.59 6.46
7 2.51 1.11 3.62 86.77 9.61
8 4.67 1.56 6.23 90.00 3.77
9 2.23 0.49 2.72 92.27 5.01
10 1.65 0.78 2.43 95.58 1.99
11 4.99 1.78 6.77 85.24 7.99
12 3.42 1.57 4.99 77.62 17.39
13 9.09 1.08 10.17 83.77 6.06
14 5.43 2.59 8.02 78.12 13.86
15 5.37 10.40 15.77 83.70 0.53
16 5.85 4.35 10.20 88.11 1.69
17 20.69 4.83 25.52 40.00 34.48
HD 8–HD 17: healthy donors (different from those shown in table 2); 1–17:
patients 1–17 with diseases other than TAP deficiency (see table 3 for details).
doi:10.1371/journal.pone.0001033.t004
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NK Cells in TAP Deficiency
PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1033more inter-individual differences were observed for CD56
dim NK
cells, of whom a mean of 49.37% were NKG2A
+ (range: 20–77%).
To compare MFI, we randomly designed a healthy donor whose
values of NKG2A MFI on both NK cell subsets were arbitrarily
considered to be 100%. The values measured in all the other
control donors and in the patients were then expressed relative to
this reference value, and we calculated means of MFI for the
different subject groups (healthy donors and patients, the latter
grouped according to similar disease states). Interestingly, it
appeared that NK cells from EFA and EMO, but not from SFH
and DFH, dramatically over-expressed NKG2A on both
CD56
bright and CD56
dim NK cells (figure 2). The difference to
the other subject groups was even more pronounced for CD56
dim
than for CD56
bright NK cells. Mean values of healthy donors and
other patients were much lower (figure 2). When looking at every
individual, none of the healthy donors and the other patients,
including those with increased CD56
bright percentages, displayed
such high MFI of NKG2A on either subset (data not shown). In
accordance with the literature [1,28], the higher expression level of
NKG2A on CD56
bright, compared to CD56
dim NK cells, was
clearly confirmed in each individual except EFA and EMO with
comparable MFI on both subsets (data not shown). Thus, in
contrast to the proportion of CD56
bright NK cells that might
increase in several different pathologic conditions, over-expression
of NKG2A was found exclusively in the two symptomatic TAP-
deficient patients.
The inhibitory receptor ILT2 is over-expressed in
symptomatic and asymptomatic TAP-deficient
patients
We asked if the broad spectrum IR ILT2 might likewise be over-
expressed at the surface of TAP-deficient NK cells, whereas we
had previously shown that members of the KIR family, with
a restricted number of HLA class I ligands, are normally expressed
in these patients [24]. As previously reported by others [1,28],
ILT2 was predominantly, but not exclusively, expressed by
CD56
dim NK cells, and percentages of ILT2
+ NK cells
considerably differed between donors. Regarding the expression
levels of ILT2, that we considered only on CD56
dim NK cells, they
were strongly augmented on CD56
dim NK cells from EFA, EMO
and DFH, although not as importantly as for NKG2A. SFH NK
cells also over-expressed ILT2 to some extent compared to the
mean of MFI from healthy donors and patients other than those
with TAP deficiency (figure 3). Mean values of different subject
groups were calculated in the same way as for NKG2A (see above).
At the individual level, one control donor and five patients had
MFI higher than SFH but clearly lower than the three other TAP-
deficient patients. Interestingly, MFI of ILT2 on T cells, B cells
and monocytes from TAP-deficient patients were not increased
but were in the range of the values seen in the healthy donors and
the other patients (data not shown), which suggests that the over-
expression of ILT2 specifically by NK cells might have some
Figure 2. Dramatic over-expression of NKG2A on both CD56
bright and CD56
dim NK cell subsets of symptomatic TAP-deficient patients. Mean
fluorescence intensities (MFI) of NKG2A were expressed relative to the values of a randomly chosen healthy donor arbitrarily considered as 100%.
Mean values of different subject groups were calculated. ND: normal donors (n=17); CF: cystic fibrosis patients (N=2), V: vasculitis patients (n=5), inf.
R.I.: infected respiratory insufficiency (n=5), uninf. R.I.: uninfected respiratory insufficiency (n=5); EFA, EMO: symptomatic TAP-deficient patients;
DFH, SFH: asymptomatic TAP-deficient patients.
doi:10.1371/journal.pone.0001033.g002
NK Cells in TAP Deficiency
PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e1033biological significance. Even if care should be taken in the context
of the low number of TAP-deficient individuals included in this
study, our results nevertheless indicate that ILT2 over-expression
might be a more consistent finding in this disease than NKG2A
over-expression, and that it might be less dependent on the
presence of clinical symptoms.
Lysis of TAP-deficient PHA-induced T cell blasts is
not restored by antibodies masking autologous NK
cell inhibitory receptors
We previously demonstrated [24,25] that activated NK cells from
TAP-deficient patients strongly lyse autologous EBV-transformed
B lymphoblasts and skin fibroblasts. NK cell inhibitory receptors
are therefore unlikely to play any protective role in this situation.
In contrast, PHA-induced T cell blasts of the patients are resistant
to autologous NK cell-mediated killing, whereas masking of HLA
class I molecules with Ab does not restore lysis [26]. To complete
these studies, we performed cytotoxicity assays with activated NK
cells from patient EMO as effectors and autologous PHA-induced
T cell blasts as targets, in the absence or presence of several Ab.
Confirming our previous results [26], target cells were completely
protected from lysis in the absence of Ab and in the presence of
anti-HLA Ab (figure 4). Interestingly, killing did likewise not
appear in the presence of masking Ab against KIR, ILT2 and
CD94/NKG2A (figure 4), which suggests that HLA class I-specific
IR, even the over-expressed ones, do not play a role in the
protection of PHA-induced T cell blasts from autologous NK cell-
mediated lysis. The results cannot be explained by a general
resistance of PHA-induced T cell blasts from patient EMO to NK
cell-mediated killing, because they were highly susceptible to
activated NK cells from two normal unrelated donors (figure 4).
Progressive reduction of the CD56
bright NK cell
fraction with improved clinical status of TAP-
deficient patients
The results shown for patients EFA and EMO were obtained with
PBMC harvested at the time when their TAP deficiency was
diagnosed and their respiratory symptoms were very severe.
Clinical status progressively improved over the following years due
to an intense therapeutic approach with repeated intravenous
administration of antibiotics and chest physiotherapy. In parallel,
we observed a reduction of the percentages of CD56
bright NK cells
in both patients, even if the values measured remained sub-
stantially higher than in healthy donors. Interestingly,
CD56
brightCD16
2 proportions remained globally unchanged,
whereas the lower percentages of CD56
brightCD16
dim NK cells
accounted for most of the lowering. Over time, expression levels of
NKG2A strongly diminished in both NK cell subsets of patient
EFA (yet remained higher than in normal NK cells), and only
moderately in patient EMO. Reductions of MFI of ILT2 were
modest. The percentage of CD56
dimCD16
2 NK cells strongly
decreased with time in patient EFA, but slightly increased in
patient EMO. At least regarding CD56
bright NK cells, the reduced
percentage that parallels clinical improvement could be in favor of
a link between the proportion of this subset among total NK cells
and the intensity and severity of respiratory infections.
Figure 3. Over-expression of ILT2 on CD56
dim NK cells of symptomatic and asymptomatic patients. Mean fluorescence intensities (MFI) of ILT2
were expressed relative to the values of a randomly chosen control donor arbitrarily considered as 100%. Mean values of different subject groups
were calculated. ND: normal donors (n=17); CF: cystic fibrosis patients (N=2), V: vasculitis patients (n=5), inf. R.I.: infected respiratory insufficiency
(n=5), uninf. R.I.: uninfected respiratory insufficiency (n=5); EFA, EMO: symptomatic TAP-deficient patients; DFH, SFH: asymptomatic TAP-deficient
patients.
doi:10.1371/journal.pone.0001033.g003
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In this paper, we confirm and extend our previous findings [26]
that in two TAP2-deficient patients, the percentage of CD56
bright
NK cells among total peripheral blood NK cells is very high in
comparison to healthy donors. To our knowledge, NK cell subset
distribution has not yet been investigated in detail in TAP-
deficient patients studied by other groups, so that it is currently
unknown if the distribution of CD56
bright and CD56
dim NK cells is
similar or not in these other cases. The two asymptomatic TAP-
deficient individuals [21] display anyhow normal percentages of
CD56
bright and CD56
dim NK cells and thus the increased
proportion of CD56
bright NK cells is not a constant hallmark of
human TAP deficiency.
Based on this finding, we reasoned that the high percentage of
CD56
bright NK cells could be a consequence of the chronic
infectious and inflammatory state of the patients. Indeed, among
patients with chronic inflammatory diseases other than TAP
deficiency, approximately 30% displayed CD56
bright percentages
above 10% of total NK cells, although their values never reached
those of the TAP-deficient individuals. Due to the small number
and the heterogeneity of our series that was intended as part of
a preliminary study, we cannot conclude if CD56
bright NK cell
percentages are preferentially increased in certain well-defined
disease stages or subtypes, or if this might rather occur, irrespective
of the underlying condition, in response to infections with
particular but not all microorganisms. These points would be
very interesting to address in future large scale studies, as well as
the question if CD56
bright NK cell expansions could be used as
a prognostic marker for the short- or long-term outcome of some
diseases.
We were somehow surprised to observe high CD56
bright NK cell
percentagesalsoamong30%ofthehealthycontroldonorswetested,
asitisgenerallyadmittedthatinthispopulation,CD56
brightNKcells
do not exceed 10% of all peripheral blood NK cells [1,29].
Information about acute infectious episodes preliminary to blood
sampling is not available from the group of healthy donors. This
finding would likewise benefit from being validated by much larger
series of individuals, whereby the criteria for attribution of the
‘‘healthy donor’’ status should be carefully defined.
Expansions of CD56
bright NK cells are known during reconstitu-
tion of the immune system after bone marrow grafts, where the first
lymphocytes to reappear in peripheral blood usually are CD56
bright
NK cells, and these cells also expand in patients daily treated with
a low dose of IL-2 [30]. More recently, Cac and Ballas [31]
published the case of a female patient with recalcitrant periungual
warts whose peripheral blood NK cells contrasted with the usual
situation, as the vast majority of her NK cells were of the CD56
bright
type and only a minor subset was CD56
dim.I na na t y p i c a lc a s eo fX -
SCID with Omenn syndrome-like manifestations, the patient
displayed an increased number of peripheral blood NK cells, half
of them being of the CD56
bright subtype [32].
The latter observations raise the question of the relationship
between both peripheral blood NK cell subsets, which is quite
a controversial issue still not clearly resolved. The two main views
are that either (i) CD56
bright NK cells are immature precursors of
CD56
dim NK cells, or that (ii) both NK cell types are functionally
Figure 4. TAP-deficient PHA-induced T cell blasts are resistant to killing by activated autologous NK cells even in the presence of antibodies
masking inhibitory receptors. A standard
51Chromium release assay was performed with activated NK cells from two normal donors (NK ND A, NK
ND B) and of patient EMO (NK EMO) as effectors and TAP-deficient PHA-induced T cell blasts from patient EMO as targets. The effector to target (E/T)
ratio was 6/1. Masking Ab were used at a concentration of 10 mg/ml. Indicated values correspond to the percentages of specific lysis.
doi:10.1371/journal.pone.0001033.g004
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separate hematopoietic precursors. Cited arguments in favor of
the former hypothesis are the small number of CD56
bright NK cells
in peripheral blood, their proliferation in the presence of
picomolar concentrations of IL-2, the expression of the hemato-
poietic stem cell marker CD117, the low content of cytotoxic
granules and the low cytotoxic activity [30,33,34]. However,
CD56
bright and CD56
dim NK cells display very different
repertoires of adhesion molecules and chemokine receptors
[1,35] and thus different migratory properties. In addition,
CD56
bright NK cells produce much higher amounts of cytokines
than their CD56
dim counterparts, so that both subtypes might well
be distinct and specialized effector cell populations [1,35,36]. In
a very recent review paper [37], the Caligiuri group, in contrast to
previous data in favor of the distinct effector cell hypothesis [36],
present a linear sequential model of human NK cell development,
in which CD56
bright NK cells would again be precursors of
CD56
dim NK cells. On the other hand, comparative microarrays
between purified CD56
bright and CD56
dim NK cells are strongly in
favor of the hypothesis of two distinct subtypes [38].
The findings of our study do not allow to strengthen one rather
than another of these models. If one considers that both NK cell
types are distinct effectors, it could be conceivable that CD56
bright
NK cells are increased during infectious and/or inflammatory
processes because the immune system is globally activated and
high amounts of NK cell-derived cytokines are needed as part of
the immune response. The corresponding NK cell subset would
therefore expand in these situations before going back to baseline
levels once the stimuli have disappeared. In support of this idea,
a child with human herpes virus 6 (HHV-6)-associated acute
necrotizing encephalopathy had a very high percentage of
CD56
bright NK cells in peripheral blood [39], and multiple
sclerosis patients treated with IFN-b display a progressive increase
in the percentages of CD56
bright NK cells [40]. Alternatively,
during such disease states, the turnover of CD56
dim NK cells
might be very high and the number of new NK cells generated
from bone marrow precursors would increase through a feedback
mechanism. The consequence would then be a high percentage of
immature CD56
bright NK cell precursors that appear in peripheral
blood to continuously replace CD56
dim NK cells.
In contrast to the increased percentages of CD56
bright NK cells,
over-expression of the IR NKG2A and ILT2 was exclusively
observed in the TAP-deficient patients. The former molecule was
dramatically up-regulated on both CD56
bright and CD56
dim NK
cell subsets of the two symptomatic individuals, whereas ILT2 was
over-expressed, although to a lesser extent than NKG2A, by
CD56
dim NK cells from all four TAP-deficient patients. In-
terestingly, the over-expression only implicates IR with a broad
spectrum of HLA class I ligands, but no receptors of the KIR
family [24] that have a more restricted panel of ligands. From
a finalistic point of view, this could be interpreted as an adaptation
of NK cells to the low HLA class I-expressing environment in
which they develop, as a higher expression level of broad-spectrum
IR might be able to still transmit enough inhibitory signals to the
NK cells and thus contribute to self-tolerance. On the other hand,
recent papers [41–43] have convincingly shown that NK cells have
in fact to express IR for self MHC class I molecules to become
‘‘licensed’’ [41], ‘‘armed’’ [42] or ‘‘educated’’ [43] for functional
activity, and that they remain ‘‘hyporesponsive’’ in their absence.
Thus, as resting NK cells from TAP-deficient patients express such
receptors but have no cytotoxic activity, one might postulate
another ‘‘licensing mechanism’’ that would be deficient in these
patients, or alternatively that HLA class I levels on surrounding
cells would simply be too low to correctly educate NK cells.
Further work is clearly needed to clarify these issues. However, it
should also be taken into account that even resting TAP-deficient
NK cells perform ADCC, and that IL-2-activated NK cells from
these patients are cytotoxic towards tumor cell lines and some
(EBV-transformed B cells and fibroblasts) but not other (PHA-
induced T cell blasts) autologous targets, which suggests that they
might have underwent some educational mechanism that partly
failed because self-tolerance is not constantly maintained
In the mouse, it has been shown that the inhibitory NK cell
receptor Ly49A interacts with its ligands H-2D
d or H-2D
k through
a cis interaction [44], which means that receptor and ligand are
closely associated in the membrane of a same NK cell. This cis
interaction has important functional consequences and actually
governs the inhibitory potential of Ly49A as well as its accessibility
for tetramer and Ab staining [44]. It could thus be argued that
NKG2A and/or ILT2 are not truly over-expressed in TAP
deficiency, but that the lack of ligands and, consequently, the
absence of cis interaction would render them simply more
accessible for specific Ab. At least for NKG2A, this explanation
seems rather unlikely, as (i) over-expression of NKG2A is not
a constant finding in TAP deficiency, and (ii) expression levels
diminish in parallel to clinical improvement. Regarding ILT2, the
possibility still exists but would have to be tested in the context of
the crystal structure of this receptor.
Although the over-expression of some IR might be an adaptive
mechanism to the low levels of HLA class I expression, it does not
seem to have any functional role in the regulation of the cytotoxic
activity of IL2-activated TAP-deficient NK cells, as revealed by the
absence of killing of autologous PHA-induced T cell blasts even in
the presence of anti-IR masking Ab. These data, in accordance with
our previous hypothesis [26], are in favor of the existence of an IR
with ligands different from HLA class I molecules and that would be
strongly expressed by activated TAP-deficient NK cells, the ligands
being present on the surface of PHA-induced T cell blasts, but not of
EBV-transformed B cells nor skin fibroblasts. With regard to the
identity of this IR, additional investigations are required, although
Markel et al. [20], who studied another family affected by TAP
deficiency,haveshown thatCD66aorCEACAM1isover-expressed
by NK cells of these patients and functions as an IR protecting
autologous cells. However, the patients also had a reduced
expression level of the AR NKp46, which is not the case in our
patients [26]. Thus, several different adaptive mechanisms of NK
cells might exist according to the individual cases.
In conclusion, in this paper, we provide data that extend our
knowledge on the phenotype of peripheral blood NK cells from
TAP-deficient patients. In addition, we show that percentages of
CD56
bright NK cells might exceed 10% of all peripheral blood NK
cells in a substantial fraction of patients with chronic diseases other
than TAP deficiency and even in donors considered as
immunologically normal. Therefore, it might be recommendable
to check more frequently the NK cell subset distribution in
infectious and inflammatory diseases, in order to precise the
conditions under which CD56
bright NK cells expand in vivo, and
what is the pathophysiological significance of this phenomenon.
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